GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00107206 | Cervix | CC | positive regulation of cell development | 64/2311 | 298/18723 | 5.69e-06 | 1.41e-04 | 64 |
GO:00073695 | Cervix | CC | gastrulation | 42/2311 | 185/18723 | 5.83e-05 | 8.46e-04 | 42 |
GO:00605375 | Cervix | CC | muscle tissue development | 76/2311 | 403/18723 | 9.76e-05 | 1.27e-03 | 76 |
GO:00147064 | Cervix | CC | striated muscle tissue development | 72/2311 | 384/18723 | 1.76e-04 | 2.07e-03 | 72 |
GO:00459955 | Cervix | CC | regulation of embryonic development | 19/2311 | 64/18723 | 1.78e-04 | 2.09e-03 | 19 |
GO:0033002 | Cervix | CC | muscle cell proliferation | 49/2311 | 248/18723 | 5.43e-04 | 5.24e-03 | 49 |
GO:00519603 | Cervix | CC | regulation of nervous system development | 77/2311 | 443/18723 | 1.13e-03 | 9.30e-03 | 77 |
GO:00507676 | Cervix | CC | regulation of neurogenesis | 65/2311 | 364/18723 | 1.33e-03 | 1.05e-02 | 65 |
GO:00507694 | Cervix | CC | positive regulation of neurogenesis | 43/2311 | 225/18723 | 2.25e-03 | 1.61e-02 | 43 |
GO:0014855 | Cervix | CC | striated muscle cell proliferation | 18/2311 | 76/18723 | 4.45e-03 | 2.71e-02 | 18 |
GO:00519622 | Cervix | CC | positive regulation of nervous system development | 48/2311 | 272/18723 | 6.60e-03 | 3.65e-02 | 48 |
GO:00605376 | Endometrium | AEH | muscle tissue development | 83/2100 | 403/18723 | 2.57e-08 | 1.50e-06 | 83 |
GO:00147065 | Endometrium | AEH | striated muscle tissue development | 75/2100 | 384/18723 | 1.06e-06 | 3.62e-05 | 75 |
GO:00330022 | Endometrium | AEH | muscle cell proliferation | 51/2100 | 248/18723 | 1.26e-05 | 2.77e-04 | 51 |
GO:00107207 | Endometrium | AEH | positive regulation of cell development | 57/2100 | 298/18723 | 3.72e-05 | 6.49e-04 | 57 |
GO:00459956 | Endometrium | AEH | regulation of embryonic development | 18/2100 | 64/18723 | 1.65e-04 | 2.15e-03 | 18 |
GO:0048738 | Endometrium | AEH | cardiac muscle tissue development | 43/2100 | 236/18723 | 9.06e-04 | 8.30e-03 | 43 |
GO:0035265 | Endometrium | AEH | organ growth | 33/2100 | 178/18723 | 2.53e-03 | 1.87e-02 | 33 |
GO:00507677 | Endometrium | AEH | regulation of neurogenesis | 56/2100 | 364/18723 | 8.87e-03 | 4.82e-02 | 56 |
GO:006053713 | Endometrium | EEC | muscle tissue development | 82/2168 | 403/18723 | 2.14e-07 | 9.38e-06 | 82 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TENM4 | SNV | Missense_Mutation | | c.191N>A | p.Val64Glu | p.V64E | Q6N022 | protein_coding | tolerated_low_confidence(0.1) | probably_damaging(0.988) | TCGA-A1-A0SM-01 | Breast | breast invasive carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
TENM4 | SNV | Missense_Mutation | | c.2228N>A | p.Thr743Asn | p.T743N | Q6N022 | protein_coding | tolerated(0.15) | benign(0.254) | TCGA-A2-A04V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | PD |
TENM4 | SNV | Missense_Mutation | rs756075933 | c.5105N>A | p.Arg1702His | p.R1702H | Q6N022 | protein_coding | tolerated(0.14) | probably_damaging(0.991) | TCGA-A2-A0CM-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | PD |
TENM4 | SNV | Missense_Mutation | rs750647178 | c.1855A>G | p.Lys619Glu | p.K619E | Q6N022 | protein_coding | deleterious(0.01) | benign(0.187) | TCGA-A2-A1FW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD |
TENM4 | SNV | Missense_Mutation | | c.6389T>C | p.Ile2130Thr | p.I2130T | Q6N022 | protein_coding | deleterious(0) | probably_damaging(0.977) | TCGA-A2-A25B-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | PD |
TENM4 | SNV | Missense_Mutation | | c.6748G>T | p.Asp2250Tyr | p.D2250Y | Q6N022 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-A8-A07R-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Ancillary | zoledronic | SD |
TENM4 | SNV | Missense_Mutation | rs750647178 | c.1855A>G | p.Lys619Glu | p.K619E | Q6N022 | protein_coding | deleterious(0.01) | benign(0.187) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
TENM4 | SNV | Missense_Mutation | | c.6110C>A | p.Thr2037Lys | p.T2037K | Q6N022 | protein_coding | deleterious(0.02) | benign(0.103) | TCGA-AC-A2FE-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD |
TENM4 | SNV | Missense_Mutation | novel | c.1456N>T | p.Pro486Ser | p.P486S | Q6N022 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TENM4 | SNV | Missense_Mutation | rs750647178 | c.1855N>G | p.Lys619Glu | p.K619E | Q6N022 | protein_coding | deleterious(0.01) | benign(0.187) | TCGA-AR-A1AY-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unspecific | Doxorubicin | SD |